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The antimalarial artemisin (Chinese: qinghaosu; 
belonging to the traditional Chinese medicine) is 
the active principle extract of the plant qinghao 
[Artemisia annua Linnnaeus (L.)]. This plant 
belongs to the family of Asterbaceae composed of 
more than 23,000 species. Artemisia vulgaris L 
(mugwort or common wormwood) is one of sev-
eral species in the genus Artemisia and it is found 
mainly in Europe. Artemisia vulgaris L is very 
similar to Artemisia annua L.1
Antimalarial properties of this weed plant were 
discovered in China in 1972.
Because artemisin itself has physical properties, 
such as poor bioavailability, that limit its effective-
ness, semi-synthetic derivates of artemisin have 
been developed. Two of these are artesunate (water 
soluble) and artemether (lipid soluble). The water 
soluble is used orally and by injection and the lipid 
soluble is used intramuscularly. In particular, 
artesunate is a highly efficacious and relatively 
safe antimalarial agent. Consequently, artesunate is 
the most widely used of these antimalarials 
worldwide.2
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Abstract
Artemisia vulgaris L and Artemisia annua L (Chinese: qinghao) are similar plants of the Asterbaceae family. Artesunate, a 
semi-synthetic derivate of artemisin which is the active principle extract of the plant qinghao, has antimalarial properties. 
Some cases of severe allergic reactions to artesunate have been described.
The purpose of this study was to evaluate the association between positive skin tests to Artemisia vulgaris L allergen 
and a preparation of injectable artesunate.
A total of 531 children were skin prick tested with inhalants (including Artemisia vulgaris L), foods, and artesunate.
Among the 59 patients positive to Artemisia vulgaris L only one child was also positive to artesunate. No child was 
positive to artesunate in those negative to Artemisia vulgaris L.
We conclude that Artemisia vulgaris L sensitization is not associated with sensitization to artesunate; consequently, skin 
test to artesunate should not be carried out before using the drug considering the rare allergic reactions.
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According to a prospective study on 3500 
patients, artesunate and artemether are both remark-
ably well tolerated.3 Severe allergic reactions have 
been rarely reported with artesunate use.4
Severe allergic reactions to oral artesunate have 
been reported4 as well as anaphylaxis to parenteral 
artesunate. Both events are extremely uncommon in 
spite of its widespread use. Literature search reveals 
only two case reports of anaphylaxis to intravenous 
artesunate.5,6 It is poorly known whether allergic 
reactions to artesunate depend on cross-reactions to 
Artemisia vulgaris L and consequently whether sub-
jects allergic to Artemisia vulgaris L are at higher 
risk of allergic reactions to artesunate. This hypoth-
esis is biologically plausible since Artemisia annua 
L and Artemisia vulgaris L belong to the same genus. 
In the present study we evaluated in a pediatric pop-
ulation the association between positive skin tests to 
Artemisia vulgaris L allergens and a preparation of 
injectable artesunate.
Materials and methods
From September 2012 to February 2013, 530 chil-
dren (mean age, 99 months; age range, 7–211 
months; male to female ratio = 1.62) referred to the 
Allergy Unit of the Anna Meyer Children’s 
University Hospital, were consecutively evaluated 
for suspected allergy to foods or inhalants.
In particular, 29% children had history of 
asthma, 20.7% children suffered from conjunctivi-
tis and rhinitis, 13.6% children had rhinitis, 9.7% 
children had atopic dermatitis, and 10.6% children 
had history of reactions to foods.
Skin tests were performed and read after 10 
min by the same investigator in order to avoid 
variability linked to the operator. We tested all 
children with common inhalants and foods (pol-
lens, mites, molds, cat and dog epithelia, milk, 
albumen, soy, wheat, cod fish, peanut, latex; com-
mercial extracts, at 0.1 mg/mL concentration Alk 
Abellò, Milan, Italy). The pollens tested were 
grass, olive, Cupressus arizonica, Betula pendula 
(birch), Artemisia vulgaris (mugworth), Carpinus 
betulus, and Parietaria mix (pellittory). Patients 
suspected to be allergic to nuts (i.e. almond, 
hazelnut, walnut) were tested with the culprit nut 
by using the prick-to-prick method. Skin prick 
tests were performed on the volar surface of the 
forearm by using a standard 1-mm tip lancet, 
according to the recommendations of the European 
Academy of Allergy and Clinical Immunology 
group.7
Positive controls for prick and prick-to-prick 
tests were performed with histamine (Alk-Abellò, 
Milan, Italy: 10 mg/mL concentration). Normal 
saline was used as a negative control of prick and 
prick-to-prick tests.
The skin prick test results were considered posi-
tive if the difference between the mean diameter of 
the wheal and the negative control was at least of 3 
mm. Children had been off antihistamines or oral 
corticosteroids 10 days before skin testing.
Moreover, all children underwent skin prick test 
with artesunate (intravenous formulation), Guilin 
Pharmaceutical Co, Ltd., PR China) at 60 mg/mL 
concentration. Such a concentration was obtained 
by adding sodium bicarbonate at 5% to the vial. 
Given the fact that no previous studies had been 
published on skin prick tests to artesunate we 
decided to test the full strength concentration.8
Results
Three hundred and sixty-three (68.5%) out of 530 
patients were skin test positive to one or more 
allergens (Table 1). Six patients were negative to 
inhalants but they were sensitized to food (two to 
milk, one to egg, one to almond, one to hazelnut, 
and one to walnut).
Among the 59 patients positive to Artemisia 
vulgaris L only one (1.7%) child was also positive 
to artesunate with a wheal diameter of 3 mm. On 
the other hand none was positive to artesunate in 
the group of children negative to Artemisia vul-
garis L.
The child, sensitized to both Artemisia vulgaris 
L and artesunate, had a history of seasonal rhinitis 
and conjunctivitis, plus angioedema with almond 
and he was positive to almost all inhalants.
In the group of 59 patients (48 boys, 11 girls) 
sensitized to Artemisia vulgaris L, six children 
were monosensitized to such a pollen.
Moreover about half (27 children; 45.8%) of the 
59 patients positive to Artemisia vulgaris L suf-
fered from both seasonal rhinitis and conjunctivitis 
and 21 (35.6%) children had asthma.
Three out of 59 patients had an Artemisia vul-
garis L wheal diameter >8 mm, in particular the 
only patient with a double positivity to both 
Artemisia vulgaris L and artesunate had an Artemisia 
vulgaris L wheal diameter of 8 mm.
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Discussion
This is the first pediatric study about possible in 
vivo cross-reactivity between Artemisia vulgaris L 
and artesunate. According to our results there is no 
a correlation between the skin prick test to 
Artemiasia vulgaris L and the risk of being artesu-
nate sensitized.
We studied the sensitization to artesunate in chil-
dren sensitized to inhalants and in particular in the 
group of those sensitized to Artemisia vulgaris L. 
Fifty-nine out of 363 patients sensitized to inhalants 
were positive to Artemisia vulgaris but only one 
child had a double positivity to Artemisia vulgaris 
and artesunate, showing that our results were not 
affected by the fact that the study was carried out 
not in a random group of children, but in a group 
with an increased chance of a positive skin test.
According to the experience of Leonardi and co-
workers,9 17,000 patients have been treated with 
artemisin derivatives but allergic reactions occurred 
in only six cases (out of them two children). The 
incidence of allergic reactions to artemisin deriva-
tives was one out of 2833 treated patients. Such a 
low incidence of allergic reaction is in agreement 
with a recent paper showing the antiallergic prop-
erties of artesunate in mouse model.10 In the publi-
cation by Leonardi and co-workers, all six patients 
had urticaria and in two cases, who also developed 
an anaphylactic reaction, epinephrine was required 
due to the severity of the reactions. Both patients 
had previously been prescribed artesunate.9 In par-
ticular, the two children, who were treated with 
artemisin derivatives plus mefloquine, had urti-
caria, but it was not possible to prove a state of 
hypersensitivity because urticaria did not recur 
when using the drugs a second time.3 The authors 
had not investigated the role of a possible Artemisia 
species sensitization. Anyway, artemisin deriva-
tives should not be used to treat uncomplicated 
Plasmodium falciparum malaria if there is a previ-
ous history of allergic reactions after their use, or if 
an urticarial rash develops during treatment.
Dube et al.5 and Mohapatra et al.6 published case 
reports of anaphylaxis to intravenous artesunate 
administered to adults. Recently, adverse drug 
reactions to artesunate have been related to genetic 
polymorphisms of CYP 2A 6 as well as gender 
influence.11
The sensitization to Artemisia vulgaris L cannot 
predict the occurrence of allergy to artesunate, never 
mind the severity of possible reactions with the use 
of intravenous artesunate. Given the scarcity of 
reports on allergy to artesunate (fewer than 10 cases 
published in literature while more than 200 million 
treatment courses administered every year), we 
think that the presence of a positivity to artesunate 
should not be checked when intravenous adminis-
tration with this drug is required, even considering 
that such an investigation is safe and very poorly 
Table 1. Inhalants and artesunate skin tests results.
Allergen Positive children (n [%]) in the overall 
dataset (n = 530)
Positive children (n [%]) among allergic 
children (n = 363)
Dermatophagoides pteronyssinus 252 (47.5%) 252 (69.4%)
Dermatophagoides farinae 251 (47.5%) 251 (69.4%)
Grass pollen 232 (43.8%) 232 (63.9%)
Dog epithelium 157 (29.6%) 157 (43.2%)
Olive pollen 130 (24.5%) 130 (35.8%)
Cupressus arizonica pollen 127 (24%) 127 (35%)
Cat epithelium 122 (23%) 122 (33.6%)
Carpinus betulus pollen 71 (13.4%) 71 (19.6%)
Betula pendula pollen 69 (13%) 69 (19%)
Alternaria alternata 62 (11.7%) 62 (17.1%)
Artemisia vulgaris pollen 59 (11%) 59 (16.2%)
Parietaria mix 52 (9.8%) 52 (14.3%)
Horse epithelium 28 (5.3%) 28 (7.7%)
Rabbit epithelium 19 (3.6%) 19 (5.2%)
Cladosporium herbarum 8 (1.5%) 8 (2.2%)
Latex 3 (0.6%) 3 (0.8%)
Artesunate 1 (0.2%) 1 (0.3%)
Negative patients 167 (31.5%)  
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time-consuming. In the current literature, all patients 
who described having had a severe reaction to 
artesunate had not been previously investigated 
from an allergy point of view. However, since in 
high-endemic countries the World Health 
Organization12 recommends artemisin-based com-
bination treatments (ACTs) as the first-line therapy 
of uncomplicated malaria and intravenous artesu-
nate for the treatment of severe malaria, limiting the 
use of a life-saving drug because of very rare possi-
ble occurrences of severe allergic reactions may be 
unreasonable. Therefore, careful reports of severe 
adverse events when administering intravenous 
artesunate may be more reasonably encouraged. In 
low-endemic countries, considering that parenteral 
artesunate is not currently available as manufactured 
under Good Manufacturing Practices and conse-
quently is not registered by regulatory agencies, 
intravenous artesunate can only be administered in 
severe malaria with a very high parasitemia by 
expert physicians to reduce mortality in severe 
imported malaria cases.13 In this setting, in our opin-
ion, only in the rare subjects with a skin test positive 
to artesunate and a history of artemisin reaction, the 
intravenous use of such a drug should be carefully 
evaluated.
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